ABEC expands process sciences group
- ABEC said on May 6 it expanded its Process Sciences group, adding more in-house bioprocess modeling, testing, and scale-up support for drug manufacturers. - The team now spans CFD, DoE, FEA, and empirical testing — tools ABEC says help clients cut risk and reach manufacturing readiness faster. - It matters because biopharma suppliers increasingly compete on process outcomes, not just tanks, bags, and installed equipment.
Bioprocessing equipment is getting harder to sell as just equipment. That is the real story here. ABEC said on May 6 that it expanded its Process Sciences group, and the point is not simply that it hired more specialists. The point is that the company wants to be closer to the part of biomanufacturing where projects succeed or fail — scale-up, transfer, validation, and the messy handoff from process idea to commercial production. (abec.com) ### What does ABEC actually make? ABEC is a bioprocess engineering company. It sells the hardware and systems used to make biologic drugs — things like bioreactors, mixing systems, and manufacturing setups for vaccines, antibodies, and newer therapy types. But ABEC also pitches itself as a long-term manufacturing partne(abec.com)ed around its installed equipment base. (abec.com) ### What changed this week? The company said it expanded its Process Sciences group to help biopharmaceutical manufacturers accelerate development, reduce risk, and improve productivity across the bioprocess lifecycle. In plain English, ABEC is putting more weight behind the team that models how a process should behave, tests whether it really behaves that way, and helps customers move from bench (abec.com)t surprises. (abec.com) ### What does “process sciences” mean here? ABEC’s own description is pretty specific. The group uses computational fluid dynamics, Design of Experiments, finite element analysis, and empirical testing. Those are not buzzwords for their own sake — they are the tools companies use to predict mixing, stress, flow, heat tr(abec.com)ring layer between “the biology works in development” and “the factory can repeat it every time.” (abec.com) ### Why is scale-up such a big deal? Because bioprocess scale-up is where nice lab results go to die. A process that behaves well in a small vessel can shift when geometry, agitation, oxygen transfer, or material stresses change at larger scale. The catch is that biologics manufacturing is unusually sensitive — cells, proteins, and viral vectors do not always tolerate those changes gracef(abec.com)ansitions becomes more valuable than one that only ships stainless steel or single-use assemblies. That is the commercial logic behind this move. (abec.com) ### Why would customers care? Because every failed transfer or delayed validation step costs time and money. Drug manufacturers do not just buy a reactor. They buy a path to reproducible batches, regulatory confidence, and faster readiness for commercial production. If ABEC can help de-risk that path earlier, it gets pulled deeper into customer decisions — not just procurement, but proces(abec.com)an make the company harder to replace later. (abec.com) ### Is this part of a bigger industry shift? Yes — and you can see it across bioprocessing. Suppliers increasingly bundle equipment with modeling, development support, and manufacturing know-how. BioProcess International’s recent coverage has been full of the same themes: process intensification, continued verification, (abec.com), not merely deliver components on time. ABEC’s announcement fits that pattern cleanly. (bioprocessintl.com) ### So what is the real takeaway? ABEC is moving further up the value stack. The company still sells equipment, obviously, but this expansion says it wants to own more of the technical judgment around how that equipment performs in real production. In biopharma, that is where margins, stickiness, and trust usually live. (abec.com))
